Redhill Biopharma Ltd. (NASDAQ:RDHL) is set to release its earnings data before the market opens on Monday, November 13th. Analysts expect Redhill Biopharma to post earnings of ($0.72) per share for the quarter.

Shares of Redhill Biopharma Ltd. (RDHL) remained flat at $$8.28 during trading hours on Tuesday. 1,300 shares of the company’s stock traded hands, compared to its average volume of 136,661. Redhill Biopharma Ltd. has a one year low of $8.16 and a one year high of $12.65.

Several brokerages have recently weighed in on RDHL. Zacks Investment Research upgraded Redhill Biopharma from a “sell” rating to a “hold” rating in a report on Wednesday, September 27th. HC Wainwright restated a “buy” rating and set a $36.00 price target (up from $33.00) on shares of Redhill Biopharma in a report on Wednesday, October 4th. Roth Capital restated a “buy” rating and set a $27.00 price target on shares of Redhill Biopharma in a report on Wednesday, October 4th. Seaport Global Securities began coverage on Redhill Biopharma in a report on Friday, October 6th. They set a “buy” rating and a $19.00 price target for the company. Finally, UBS AG began coverage on Redhill Biopharma in a report on Wednesday, September 13th. They set a “reduce” rating for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $23.35.

TRADEMARK VIOLATION NOTICE: “Redhill Biopharma Ltd. (RDHL) Scheduled to Post Earnings on Monday” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/11/07/redhill-biopharma-ltd-rdhl-scheduled-to-post-earnings-on-monday.html.

Redhill Biopharma Company Profile

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Earnings History for Redhill Biopharma (NASDAQ:RDHL)

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.